ACTRN12606000267550招募中3 期
The Twin birth study: A multicentre randomised controlled trial comparing planned vaginal birth to planned Caesarean Section of twins more than or equal to 32 weeks gestation to assess neonatal mortality and/or serious neonatal morbidity during the first 28 days after birth.
Maternal, Infant and Reproductive Health Research Unit0 个研究点目标入组 2,800 人开始时间: 2005年4月6日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 2,800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 32 Weeks 至 38 Weeks（—）
- 性别
- Female
入选标准
- •Twins where twin A is cephalic, gestational age 32-38 weeks, estimated fetal weight 1500-4000g, both twins alive.
排除标准
- •monoamniotic twins, lethal fetal anomaly, contraindication to labour or vaginal birth.
研究者
相似试验
进行中（未招募）
不适用
the effect of the addition of pegvisomant on quality of life and glucose sensitivity in acromegaly patientsacromegalyEUCTR2011-004231-31-NLErasmus University Medical Centre Rotterdam
已完成
3 期
Randomized double blind multi-centre study of the effects on low-dose pegvisomant treatment in acromegalic subjects in whom the IGF1 levels has been normalized by long-acting somatostatin analoguessomatotrofinomas10021112AcromegalyNL-OMON39522Erasmus MC, Universitair Medisch Centrum Rotterdam60
进行中（未招募）
不适用
A multicenter double-blind randomized study to investigate the efficacy and tolerability of three doses of GS-101 eye drops, an antisense oligonucleotide, versus placebo on inhibition of corneal neovascularisation, a major risk factor of corneal graft rejection.EUCTR2004-005015-29-DEes Laboratoires CTRS100
招募中
3 期
Phase III clinical study of DRL Abatacept (DRL_AB) and Orencia in Rheumatoid Arthritis patientCTRI/2024/03/064580Dr. Reddys Laboratories Ltd.
招募中
1 期
A randomised, double-blind, multicentre study comparing the efficacy, safety and immunogenicity of proposed Abatacept biosimilar (DRL_AB) with Orencia® administered by the intravenous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritisMedDRA version: 23.1Level: LLTClassification code: 10039074Term: Rheumatoid arthritis aggravated Class: 10028395MedDRA version: 23.1Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859MedDRA version: 23.1Level: LLTClassification code: 10066578Term: Progression of rheumatoid arthritis Class: 10028395MedDRA version: 20.0Level: HLTClassification code: 10039075Term: Rheumatoid arthritis and associated conditions Class: 10021428Rheumatoid ArthritisCTIS2023-506664-14-00Dr Reddy's Laboratories Limited532